Suchergebnisse - "Goteti, Kosalaram"

PubPharm (52)

1

Safety, Tolerability, and Pharmacodynamics of the ADAMTS-5 Nanobody M6495 : Two Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies in Healthy Subjects and Patients With Osteoarthritis

enthalten in: ACR open rheumatology | 2024

von Bihlet, A. | Balchen, T. | Goteti, K. | +8

2

Asia-Inclusive Global Development of Enpatoran : Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

enthalten in: Clinical pharmacology and therapeutics | 2024

von Klopp-Schulze, L. | Gopalakrishnan, S. | Yalkinoglu, �. | +10

3

Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

enthalten in: CPT: pharmacometrics & systems pharmacology | 2024

von Goteti, K. | Garcia, R. | Gillespie, W. | +8

4

Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

enthalten in: Clinical pharmacology and therapeutics | 2024

von Vugmeyster, Y. | Ravula, A. | Rouits, E. | +7

5

Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495 : Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis

enthalten in: ACR Open Rheumatology | 2024

von Bihlet, A. | Balchen, T. | Goteti, K. | +8

6

Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

enthalten in: Clinical Pharmacology & Therapeutics | 2024

von Vugmeyster, Y. | Ravula, A. | Rouits, E. | +7

7

Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

enthalten in: CPT: Pharmacometrics & Systems Pharmacology | 2024

von Goteti, K. | Garcia, R. | Gillespie, W. | +8

8

Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective

enthalten in: Clinical pharmacology and therapeutics | 2023

von Goteti, K. | Hanan, N. | Magee, M. | +9

9

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response : Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development

enthalten in: CPT: pharmacometrics & systems pharmacology | 2023

von Goteti, K. | French, J. | Garcia, R. | +12

10

Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective

enthalten in: Clinical Pharmacology & Therapeutics | 2023

von Goteti, K. | Hanan, N. | Magee, M. | +9

1
2
3
4
5
6
Nächster »
[6]